Usefulness of Left Atrial Strain to Predict End Stage Renal Failure in Patients With Chronic Kidney Disease.


Journal

The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277

Informations de publication

Date de publication:
15 07 2021
Historique:
received: 10 01 2021
revised: 22 03 2021
accepted: 23 03 2021
pubmed: 30 5 2021
medline: 14 9 2021
entrez: 29 5 2021
Statut: ppublish

Résumé

Left atrial (LA) enlargement predicts adverse cardiovascular events in patients with chronic kidney disease (CKD). The aim of our study was to evaluate the value of LA reservoir strain, a novel measure of LA function, as a prognostic marker for adverse renal outcomes. A total of 280 patients (65.8 ± 12.2years, 63% male) with stable Stage 3 and 4 CKD without prior cardiac history were evaluated with transthoracic echocardiography and prospectively followed for up to 5 years. The primary end point was progressive renal failure, which was the composite of death from renal cause, end-stage renal failure and/or doubling of serum creatinine. Over a mean follow up of 3.9 ± 2.7years, 56 patients reached the composite endpoint. By log rank test, older age, lower baseline eGFR, anemia, diabetes mellitus, higher urinary albumin/creatinine ratio, number of antihypertensive medications, higher indexed left ventricular mass, larger LA volumes, and impaired LA reservoir strain were significant predictors of the composite outcome (p <0.01 for all). Multi-variable Cox regression analysis found LA reservoir strain, eGFR, number of antihypertensive medications and urinary albumin/creatinine ratio were independent predictors for progressive renal failure (p <0.01 for all). Impaired LA reservoir strain was associated with a 2.5-fold higher risk of the composite outcome (HR 2.51, 95% CI 1.19 to 5.30, p = 0.02) and was the only echocardiographic parameter that predicted progressive renal failure independent of established clinical risk factors for end-stage renal failure. Its utility requires validation in high risk CKD patients with cardiac disease.

Identifiants

pubmed: 34049674
pii: S0002-9149(21)00327-1
doi: 10.1016/j.amjcard.2021.03.056
pii:
doi:

Substances chimiques

Creatinine AYI8EX34EU

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

105-113

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Disclosures The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Gary C H Gan (GCH)

Department of Cardiology, Blacktown Hospital, Sydney, New South Wales, Australia; Department of Cardiology, Westmead Hospital, Sydney, New South Wales, Australia; School of Medicine,University of New South Wales, Sydney, New South Wales, Australia.

Aditya Bhat (A)

Department of Cardiology, Blacktown Hospital, Sydney, New South Wales, Australia; School of Medicine,University of New South Wales, Sydney, New South Wales, Australia.

Krishna K Kadappu (KK)

Department of Cardiology, Liverpool Hospital, Sydney, New South Wales, Australia; Department of Cardiology, Campbelltown Hospital, Sydney, New South Wales, Australia; School of Medicine,University of New South Wales, Sydney, New South Wales, Australia.

Fernando Fernandez (F)

Department of Cardiology, Blacktown Hospital, Sydney, New South Wales, Australia.

Kennith H Gu (KH)

Department of Cardiology, Blacktown Hospital, Sydney, New South Wales, Australia; School of Medicine,University of New South Wales, Sydney, New South Wales, Australia.

Henry H L Chen (HHL)

Department of Cardiology, Blacktown Hospital, Sydney, New South Wales, Australia.

Suzanne Eshoo (S)

Department of Cardiology, Blacktown Hospital, Sydney, New South Wales, Australia.

Brian Nankivell (B)

Department of Renal Medicine, Westmead Hospital, Sydney, New South Wales, Australia.

Liza Thomas (L)

Department of Cardiology, Westmead Hospital, Sydney, New South Wales, Australia; School of Medicine,University of New South Wales, Sydney, New South Wales, Australia; School of Medicine, University of Sydney, Sydney, New South Wales, Australia. Electronic address: l.thomas@unsw.edu.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH